false2021Q10001549084--12-3191P5DP5Dfive years, six months5.500015490842022-01-012022-03-3100015490842022-04-25xbrli:shares00015490842022-03-31iso4217:USD00015490842021-12-31iso4217:USDxbrli:shares00015490842021-01-012021-03-310001549084us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2021-12-310001549084us-gaap:CommonStockMember2021-12-310001549084us-gaap:AdditionalPaidInCapitalMember2021-12-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001549084us-gaap:RetainedEarningsMember2021-12-310001549084us-gaap:RetainedEarningsMember2022-01-012022-03-310001549084us-gaap:CommonStockMember2022-01-012022-03-310001549084us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001549084us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2022-03-310001549084us-gaap:CommonStockMember2022-03-310001549084us-gaap:AdditionalPaidInCapitalMember2022-03-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001549084us-gaap:RetainedEarningsMember2022-03-310001549084us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2020-12-310001549084us-gaap:CommonStockMember2020-12-310001549084us-gaap:AdditionalPaidInCapitalMember2020-12-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001549084us-gaap:RetainedEarningsMember2020-12-3100015490842020-12-310001549084us-gaap:RetainedEarningsMember2021-01-012021-03-310001549084us-gaap:CommonStockMember2021-01-012021-03-310001549084us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001549084us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2021-03-310001549084us-gaap:CommonStockMember2021-03-310001549084us-gaap:AdditionalPaidInCapitalMember2021-03-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001549084us-gaap:RetainedEarningsMember2021-03-3100015490842021-03-310001549084us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-31ekso:customer0001549084us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001549084us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001549084us-gaap:RevenueFromContractWithCustomerMemberekso:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-31xbrli:pure0001549084us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001549084us-gaap:RevenueFromContractWithCustomerMemberekso:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001549084us-gaap:RevenueFromContractWithCustomerMemberekso:CustomerBMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001549084us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001549084us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001549084us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310001549084us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310001549084us-gaap:FairValueMeasurementsRecurringMember2022-03-310001549084us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001549084us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001549084us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310001549084us-gaap:FairValueMeasurementsRecurringMember2021-12-310001549084us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001549084us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001549084us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001549084us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-12-310001549084us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-01-012022-03-310001549084us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-03-310001549084srt:MinimumMemberekso:EksoHealthMember2022-01-012022-03-310001549084srt:MaximumMemberekso:EksoHealthMember2022-01-012022-03-3100015490842022-04-012022-03-3100015490842023-01-012022-03-3100015490842024-01-012022-03-310001549084us-gaap:RoyaltyMember2022-01-012022-03-310001549084ekso:AccountsReceivableNetAndOtherAssetsMember2022-03-310001549084ekso:AccountsReceivableNetAndOtherAssetsMember2021-12-310001549084srt:MinimumMember2022-01-012022-03-310001549084srt:MaximumMember2022-01-012022-03-310001549084us-gaap:ProductMemberekso:EksoHealthMember2022-01-012022-03-310001549084us-gaap:ProductMemberekso:EksoWorksMember2022-01-012022-03-310001549084us-gaap:ProductMember2022-01-012022-03-310001549084us-gaap:ServiceMemberekso:EksoHealthMember2022-01-012022-03-310001549084ekso:EksoWorksMemberus-gaap:ServiceMember2022-01-012022-03-310001549084us-gaap:ServiceMember2022-01-012022-03-310001549084ekso:SubscriptionsMemberekso:EksoHealthMember2022-01-012022-03-310001549084ekso:EksoWorksMemberekso:SubscriptionsMember2022-01-012022-03-310001549084ekso:SubscriptionsMember2022-01-012022-03-310001549084us-gaap:ProductAndServiceOtherMemberekso:EksoHealthMember2022-01-012022-03-310001549084ekso:EksoWorksMemberus-gaap:ProductAndServiceOtherMember2022-01-012022-03-310001549084us-gaap:ProductAndServiceOtherMember2022-01-012022-03-310001549084ekso:CollaborativeArrangementsMemberekso:EksoHealthMember2022-01-012022-03-310001549084ekso:EksoWorksMemberekso:CollaborativeArrangementsMember2022-01-012022-03-310001549084ekso:CollaborativeArrangementsMember2022-01-012022-03-310001549084ekso:EksoHealthMember2022-01-012022-03-310001549084ekso:EksoWorksMember2022-01-012022-03-310001549084us-gaap:ProductMemberekso:EksoHealthMember2021-01-012021-03-310001549084us-gaap:ProductMemberekso:EksoWorksMember2021-01-012021-03-310001549084us-gaap:ProductMember2021-01-012021-03-310001549084us-gaap:ServiceMemberekso:EksoHealthMember2021-01-012021-03-310001549084ekso:EksoWorksMemberus-gaap:ServiceMember2021-01-012021-03-310001549084us-gaap:ServiceMember2021-01-012021-03-310001549084ekso:RentalsAndSubscriptionsMemberekso:EksoHealthMember2021-01-012021-03-310001549084ekso:RentalsAndSubscriptionsMemberekso:EksoWorksMember2021-01-012021-03-310001549084ekso:RentalsAndSubscriptionsMember2021-01-012021-03-310001549084us-gaap:ProductAndServiceOtherMemberekso:EksoHealthMember2021-01-012021-03-310001549084ekso:EksoWorksMemberus-gaap:ProductAndServiceOtherMember2021-01-012021-03-310001549084us-gaap:ProductAndServiceOtherMember2021-01-012021-03-310001549084ekso:CollaborativeArrangementsMemberekso:EksoHealthMember2021-01-012021-03-310001549084ekso:EksoWorksMemberekso:CollaborativeArrangementsMember2021-01-012021-03-310001549084ekso:CollaborativeArrangementsMember2021-01-012021-03-310001549084ekso:EksoHealthMember2021-01-012021-03-310001549084ekso:EksoWorksMember2021-01-012021-03-310001549084ekso:WarrantyMember2021-12-310001549084ekso:WarrantyMember2022-01-012022-03-310001549084ekso:WarrantyMember2022-03-310001549084ekso:TermLoanMemberekso:PWBLoanAgreementMember2020-08-310001549084ekso:TermLoanMemberus-gaap:PrimeRateMemberekso:PWBLoanAgreementMember2020-08-012020-08-300001549084ekso:TermLoanMemberekso:PWBLoanAgreementMember2022-03-310001549084ekso:TermLoanMemberekso:PWBLoanAgreementMember2022-01-012022-03-310001549084us-gaap:UnsecuredDebtMember2020-04-200001549084us-gaap:UnsecuredDebtMember2020-04-202020-04-200001549084us-gaap:UnsecuredDebtMember2021-06-282021-06-280001549084ekso:RichmondCaliforniaMember2022-03-310001549084ekso:HamburgGermanyMember2022-03-310001549084ekso:HamburgGermanyMember2022-02-28ekso:extension0001549084ekso:February2021OfferingMemberus-gaap:OverAllotmentOptionMember2021-01-012021-02-280001549084ekso:February2021OfferingMemberus-gaap:OverAllotmentOptionMember2021-02-280001549084ekso:February2021OfferingMember2021-01-012021-02-280001549084ekso:A2021WarrantsMember2021-02-280001549084ekso:February2021OfferingMember2021-02-280001549084ekso:AtTheMarketOfferingMember2020-10-012020-10-290001549084ekso:AtTheMarketOfferingMember2020-10-290001549084ekso:AtTheMarketOfferingMember2022-01-012022-03-310001549084us-gaap:CommonStockMemberekso:AtTheMarketOfferingMember2022-01-012022-03-310001549084ekso:A2021WarrantsMember2022-03-310001549084ekso:A2021WarrantsMember2022-01-012022-03-310001549084ekso:June2020InvestorWarrantsMember2022-03-310001549084ekso:June2020InvestorWarrantsMember2022-01-012022-03-310001549084ekso:June2020InvestorWarrantsMember2021-12-310001549084ekso:June2020PlacementAgentWarrantsMember2020-06-300001549084ekso:June2020PlacementAgentWarrantsMember2022-01-012022-03-310001549084ekso:June2020PlacementAgentWarrantsMember2021-12-310001549084ekso:June2020PlacementAgentWarrantsMember2022-03-310001549084ekso:December2019WarrantsMember2022-03-310001549084ekso:December2019WarrantsMember2022-01-012022-03-310001549084ekso:December2019WarrantsMember2021-12-310001549084ekso:December2019PlacementAgentWarrantsMember2022-03-310001549084ekso:December2019PlacementAgentWarrantsMember2022-01-012022-03-310001549084ekso:December2019PlacementAgentWarrantsMember2021-12-310001549084ekso:May2019WarrantsMember2022-03-310001549084ekso:May2019WarrantsMember2022-01-012022-03-310001549084ekso:May2019WarrantsMember2021-12-310001549084ekso:A2021WarrantsMember2021-01-012021-02-280001549084us-gaap:MeasurementInputSharePriceMemberekso:A2021WarrantsMember2022-03-310001549084us-gaap:MeasurementInputSharePriceMemberekso:A2021WarrantsMember2021-12-310001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-03-310001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputConversionPriceMember2021-01-012021-12-310001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-03-310001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-03-310001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-12-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:A2021WarrantsMember2022-03-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:A2021WarrantsMember2021-12-310001549084ekso:June2020InvestorWarrantsMember2020-06-300001549084ekso:June2020InvestorWarrantsMember2021-01-012021-03-310001549084ekso:June2020InvestorWarrantsMember2020-06-012020-06-300001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputSharePriceMember2022-03-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputSharePriceMember2021-12-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-03-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputConversionPriceMember2021-01-012021-12-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-03-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-03-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-12-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2022-03-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-12-310001549084ekso:June2020PlacementAgentWarrantsMember2020-06-012020-06-300001549084ekso:June2020PlacementAgentWarrantsMember2021-01-012021-03-310001549084us-gaap:MeasurementInputSharePriceMemberekso:June2020PlacementAgentWarrantsMember2022-03-310001549084us-gaap:MeasurementInputSharePriceMemberekso:June2020PlacementAgentWarrantsMember2021-12-310001549084ekso:June2020PlacementAgentWarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-03-310001549084ekso:June2020PlacementAgentWarrantsMemberus-gaap:MeasurementInputConversionPriceMember2021-01-012021-12-310001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:June2020PlacementAgentWarrantsMember2022-03-310001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:June2020PlacementAgentWarrantsMember2021-12-310001549084us-gaap:MeasurementInputExpectedTermMemberekso:June2020PlacementAgentWarrantsMember2022-03-310001549084us-gaap:MeasurementInputExpectedTermMemberekso:June2020PlacementAgentWarrantsMember2021-12-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:June2020PlacementAgentWarrantsMember2022-03-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:June2020PlacementAgentWarrantsMember2021-12-310001549084ekso:December2019WarrantsMember2019-12-310001549084ekso:December2019WarrantsMember2019-12-012019-12-310001549084us-gaap:MeasurementInputSharePriceMemberekso:December2019WarrantsMember2022-03-310001549084us-gaap:MeasurementInputSharePriceMemberekso:December2019WarrantsMember2021-12-310001549084ekso:December2019WarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-03-310001549084ekso:December2019WarrantsMemberus-gaap:MeasurementInputConversionPriceMember2021-01-012021-12-310001549084ekso:December2019WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-03-310001549084ekso:December2019WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001549084ekso:December2019WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-03-310001549084ekso:December2019WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-12-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:December2019WarrantsMember2022-03-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:December2019WarrantsMember2021-12-310001549084ekso:December2019PlacementAgentWarrantsMember2019-12-310001549084us-gaap:MeasurementInputSharePriceMemberekso:December2019PlacementAgentWarrantsMember2022-03-310001549084us-gaap:MeasurementInputSharePriceMemberekso:December2019PlacementAgentWarrantsMember2021-12-310001549084ekso:December2019PlacementAgentWarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-03-310001549084ekso:December2019PlacementAgentWarrantsMemberus-gaap:MeasurementInputConversionPriceMember2021-01-012021-12-310001549084ekso:December2019PlacementAgentWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-03-310001549084ekso:December2019PlacementAgentWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001549084ekso:December2019PlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-03-310001549084ekso:December2019PlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-12-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:December2019PlacementAgentWarrantsMember2022-03-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:December2019PlacementAgentWarrantsMember2021-12-310001549084ekso:May2019WarrantsMember2019-05-310001549084ekso:May2019WarrantsMember2020-06-300001549084ekso:May2019WarrantsMemberus-gaap:CommonStockMemberekso:DirectOfferingMember2020-06-300001549084ekso:June2020WarrantsMember2020-06-300001549084ekso:May2019WarrantsMember2021-01-012021-03-310001549084ekso:May2019WarrantsMember2019-05-012019-05-300001549084us-gaap:MeasurementInputSharePriceMemberekso:May2019WarrantsMember2022-03-310001549084us-gaap:MeasurementInputSharePriceMemberekso:May2019WarrantsMember2021-12-310001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-03-310001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputConversionPriceMember2021-01-012021-12-310001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-03-310001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-03-310001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-12-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:May2019WarrantsMember2022-03-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:May2019WarrantsMember2021-12-310001549084ekso:June2020WarrantsMember2022-01-012022-03-310001549084ekso:EquityIncentivePlan2014Member2022-03-310001549084ekso:EquityIncentivePlan2014Member2021-12-310001549084ekso:EquityIncentivePlan2014Member2022-01-012022-03-310001549084ekso:EquityIncentivePlan2014Member2022-03-310001549084us-gaap:EmployeeStockOptionMember2022-03-310001549084us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001549084us-gaap:RestrictedStockUnitsRSUMember2022-03-310001549084us-gaap:RestrictedStockUnitsRSUMember2021-12-310001549084us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001549084us-gaap:SellingAndMarketingExpenseMember2022-01-012022-03-310001549084us-gaap:SellingAndMarketingExpenseMember2021-01-012021-03-310001549084us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001549084us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001549084us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001549084us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-3100015490842021-01-012021-12-3100015490842020-01-012020-12-310001549084us-gaap:RoyaltyAgreementTermsMember2022-03-31ekso:license_agreement0001549084ekso:SalesRevenueGoodsNetExcludingGovernmentSalesMemberus-gaap:RoyaltyAgreementTermsMember2022-01-012022-03-310001549084ekso:LicenseRevenueMemberus-gaap:RoyaltyAgreementTermsMember2022-01-012022-03-310001549084us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001549084us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001549084us-gaap:RestrictedStockMember2022-01-012022-03-310001549084us-gaap:RestrictedStockMember2021-01-012021-03-310001549084us-gaap:WarrantMember2022-01-012022-03-310001549084us-gaap:WarrantMember2021-01-012021-03-31ekso:segment0001549084country:US2022-01-012022-03-310001549084country:US2021-01-012021-03-310001549084ekso:AmericasOtherMember2022-01-012022-03-310001549084ekso:AmericasOtherMember2021-01-012021-03-310001549084srt:AmericasMember2022-01-012022-03-310001549084srt:AmericasMember2021-01-012021-03-310001549084country:DE2022-01-012022-03-310001549084country:DE2021-01-012021-03-310001549084ekso:EMEAOtherMember2022-01-012022-03-310001549084ekso:EMEAOtherMember2021-01-012021-03-310001549084us-gaap:EMEAMember2022-01-012022-03-310001549084us-gaap:EMEAMember2021-01-012021-03-310001549084country:JP2022-01-012022-03-310001549084country:JP2021-01-012021-03-310001549084country:SG2022-01-012022-03-310001549084country:SG2021-01-012021-03-310001549084ekso:APACOtherMember2022-01-012022-03-310001549084ekso:APACOtherMember2021-01-012021-03-310001549084srt:AsiaPacificMember2022-01-012022-03-310001549084srt:AsiaPacificMember2021-01-012021-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________________________________________
FORM 10-Q
____________________________________________________________________________________________ | | | | | |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2022
or | | | | | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ______ to ______
Commission File Number: 001-37854
____________________________________________________________________________________________
Ekso Bionics Holdings, Inc.
(Exact name of registrant as specified in its charter)
____________________________________________________________________________________________ | | | | | | | | |
Nevada | | 99-0367049 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
| | | | | | | | |
1414 Harbour Way South, Suite 1201 Richmond, CA | | 94804 |
(Address of principal executive offices) | | (Zip Code) |
(510) 984-1761
(Registrant’s telephone number, including area code)
________________________________
(Former name, former address, and former fiscal year, if changed since last report)
____________________________________________________________________________________________
Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Name of each exchange on which registered: | | | | | | | | | | | | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, $0.001 par value per share | | EKSO | | Nasdaq Capital Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. | | | | | | | | | | | | | | |
Large accelerated filer | ☐ | | Accelerated filer | ☐ |
| | | | |
Non-accelerated filer | ☒ | | Smaller reporting company | ☒ |
| | | | |
| | | Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
The number of shares of registrant’s common stock outstanding as of April 25, 2022 was 12,844,501.
Ekso Bionics Holdings, Inc.
Quarterly Report on Form 10-Q
Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Ekso Bionics Holdings, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except par value)
| | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
| (unaudited) | | (Note 2) |
Assets | | | |
Current assets: | | | |
Cash | $ | 36,176 | | | $ | 40,406 | |
Accounts receivable, net of allowances of $19 and $28, respectively | 3,346 | | | 4,662 | |
Inventories | 2,772 | | | 2,242 | |
Prepaid expenses and other current assets | 829 | | | 485 | |
Total current assets | 43,123 | | | 47,795 | |
Property and equipment, net | 886 | | | 991 | |
Right-of-use assets | 92 | | | 216 | |
Other assets | 141 | | | 164 | |
Total assets | $ | 44,242 | | | $ | 49,166 | |
Liabilities and Stockholders’ Equity | | | |
Current liabilities: | | | |
Accounts payable | $ | 2,939 | | | $ | 3,107 | |
Accrued liabilities | 1,819 | | | 2,299 | |
Deferred revenues, current | 1,115 | | | 1,220 | |
| | | |
Lease liabilities, current | 97 | | | 229 | |
Total current liabilities | 5,970 | | | 6,855 | |
Deferred revenues | 1,082 | | | 1,475 | |
Notes payable, net | 1,994 | | | 1,993 | |
| | | |
Warrant liabilities | 1,650 | | | 1,550 | |
Other non-current liabilities | 60 | | | 74 | |
Total liabilities | 10,756 | | | 11,947 | |
Commitments and contingencies (Note 13) | | | |
Stockholders’ equity: | | | |
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding at March 31, 2022 and December 31, 2021 | — | | | — | |
Common stock, $0.001 par value; 141,429 shares authorized; 12,844 and 12,693 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively | 13 | | | 13 | |
Additional paid-in capital | 246,765 | | | 246,090 | |
Accumulated other comprehensive gain (loss) | 195 | | | (17) | |
Accumulated deficit | (213,487) | | | (208,867) | |
Total stockholders’ equity | 33,486 | | | 37,219 | |
Total liabilities and stockholders’ equity | $ | 44,242 | | | $ | 49,166 | |
The accompanying notes are an integral part of these condensed consolidated financial statements
Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)
| | | | | | | | | | | | | | | | | |
| | | Three Months Ended March 31, |
| | | | | 2022 | | 2021 |
Revenue | | | | | $ | 2,567 | | | $ | 1,910 | |
Cost of revenue | | | | | 1,358 | | | 675 | |
Gross profit | | | | | 1,209 | | | 1,235 | |
| | | | | | | |
Operating expenses: | | | | | | | |
Sales and marketing | | | | | 1,629 | | | 1,793 | |
Research and development | | | | | 999 | | | 603 | |
General and administrative | | | | | 2,818 | | | 1,978 | |
| | | | | | | |
| | | | | | | |
Total operating expenses | | | | | 5,446 | | | 4,374 | |
| | | | | | | |
Loss from operations | | | | | (4,237) | | | (3,139) | |
| | | | | | | |
Other expense, net: | | | | | | | |
Interest expense | | | | | (27) | | | (26) | |
(Loss) gain on revaluation of warrant liabilities | | | | | (100) | | | 11 | |
| | | | | | | |
| | | | | | | |
Other expense, net | | | | | (256) | | | (516) | |
Total other expense, net | | | | | (383) | | | (531) | |
| | | | | | | |
Net loss | | | | | $ | (4,620) | | | $ | (3,670) | |
Other comprehensive income | | | | | 212 | | | 465 | |
Comprehensive loss | | | | | $ | (4,408) | | | $ | (3,205) | |
| | | | | | | |
Net loss per share applicable to common shareholders, basic and diluted | | | | | $ | (0.36) | | | $ | (0.34) | |
| | | | | | | |
| | | | | | | |
Weighted average number of shares outstanding, basic and diluted | | | | | 12,728 | | | 10,752 | |
| | | | | | | |
The accompanying notes are an integral part of these condensed consolidated financial statements
Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands)
(Unaudited) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Convertible Preferred Stock | | Common Stock | | Additional Paid-in Capital | | Accumulated Other Comprehensive (Loss) Income | | Accumulated Deficit | | Total Stockholders’ Equity |
| Shares | | Amount | | Shares | | Amount | | | | |
Balance at December 31, 2021 | — | | | $ | — | | | 12,693 | | | $ | 13 | | | $ | 246,090 | | | $ | (17) | | | $ | (208,867) | | | $ | 37,219 | |
Net loss | — | | | — | | | — | | | — | | | — | | | — | | | (4,620) | | | (4,620) | |
Issuance of common stock under: | | | | | | | | | | | | | | | |
Matching contribution to 401(k) plan | — | | | — | | | 68 | | | — | | | 176 | | | — | | | — | | | 176 | |
Equity incentive plan | — | | | — | | | 83 | | | — | | | — | | | — | | | — | | | — | |
| | | | | | | | | | | | | | | |
Stock-based compensation expense | — | | | — | | | — | | | — | | | 499 | | | — | | | — | | | 499 | |
Foreign currency translation adjustments | — | | | — | | | — | | | — | | | — | | | 212 | | | — | | | 212 | |
Balance at March 31, 2022 | — | | | $ | — | | | 12,844 | | | $ | 13 | | | $ | 246,765 | | | $ | 195 | | | $ | (213,487) | | | $ | 33,486 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Convertible Preferred Stock | | Common Stock | | Additional Paid-in Capital | | Accumulated Other Comprehensive (Loss) Income | | Accumulated Deficit | | Total Stockholders’ Equity |
| Shares | | Amount | | Shares | | Amount | | | | |
Balance at December 31, 2020 | — | | | $ | — | | | 8,349 | | | $ | 8 | | | $ | 204,376 | | | $ | (847) | | | $ | (199,103) | | | $ | 4,434 | |
Net loss | — | | | — | | | — | | | — | | | — | | | — | | | (3,670) | | | (3,670) | |
Issuance of common stock under: | | | | | | | | | | | | | | | |
Equity financing, net | — | | | — | | | 3,980 | | | 4 | | | 35,356 | | | — | | | — | | | 35,360 | |
Exercise of warrants | — | | | — | | | 300 | | | 1 | | | 3,877 | | | — | | | — | | | 3,878 | |
Matching contribution to 401(k) plan | — | | | — | | | 26 | | | — | | | 152 | | | — | | | — | | | 152 | |
Stock-based compensation expense | — | | | — | | | — | | | — | | | 356 | | | — | | | — | | | 356 | |
Foreign currency translation adjustments | — | | | — | | | — | | | — | | | — | | | 465 | | | — | | | 465 | |
Balance at March 31, 2021 | — | | | $ | — | | | 12,655 | | | $ | 13 | | | $ | 244,117 | | | $ | (382) | | | $ | (202,773) | | | $ | 40,975 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
The accompanying notes are an integral part of these condensed consolidated financial statements
Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited) | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2022 | | 2021 |
Operating activities: | | | |
Net loss | $ | (4,620) | | | $ | (3,670) | |
Adjustments to reconcile net loss to net cash used in operating activities | | | |
Depreciation | 131 | | | 126 | |
Changes in allowance for doubtful accounts | (9) | | | 31 | |
| | | |
| | | |
Loss (gain) on revaluation of warrant liabilities | 100 | | | (11) | |
| | | |
Stock-based compensation expense | 499 | | | 356 | |
Common stock contribution to 401(k) plan | 64 | | | 52 | |
| | | |
Unrealized loss on foreign currency transactions | 254 | | | 503 | |
Changes in operating assets and liabilities: | | | |
Accounts receivable | 1,297 | | | 917 | |
Inventories | (562) | | | (228) | |
Prepaid expenses, right-of-use assets, and other assets | (203) | | | (78) | |
Accounts payable | (166) | | | 151 | |
Accrued, lease and other liabilities | (503) | | | 16 | |
Deferred revenues | (488) | | | (165) | |
Net cash used in operating activities | (4,206) | | | (2,000) | |
| | | |
| | | |
| | | |
Financing activities: | | | |
Proceeds from issuance of common stock and warrants, net | — | | | 37,295 | |
| | | |
| | | |
| | | |
Proceeds from exercise of warrants | — | | | 1,417 | |
Net cash provided by financing activities | — | | | 38,712 | |
Effect of exchange rate changes on cash | (24) | | | (35) | |
Net (decrease) increase in cash | (4,230) | | | 36,677 | |
Cash at beginning of period | 40,406 | | | 12,862 | |
Cash at end of period | $ | 36,176 | | | $ | 49,539 | |
| | | |
Supplemental disclosure of cash flow activities | | | |
Cash paid for interest | $ | 27 | | | $ | 23 | |
| | | |
| | | |
Supplemental disclosure of non-cash activities | | | |
Fair value of warrants issued upon equity financing | $ | — | | | $ | 1,936 | |
Reclassification of warrant liability to equity upon exercise of warrants | $ | — | | | $ | 2,461 | |
Transfer of inventory to (from) property and equipment | $ | 29 | | | $ | 53 | |
Share issuance for common stock contribution to 401(k) plan | $ | 176 | | | $ | 152 | |
| | | |
The accompanying notes are an integral part of these condensed consolidated financial statements
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
1. Organization
Description of Business
Ekso Bionics Holdings, Inc. (the “Company”) designs, develops, and markets exoskeleton products to augment human strength, endurance and mobility. The Company’s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and by persons with physical disabilities. The Company has marketed devices that (i) enable individuals with neurological conditions affecting gait, including acquired brain injury ("ABI") and spinal cord injury ("SCI"), to rehabilitate and to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods. Founded in 2005, the Company is headquartered in the San Francisco Bay area and listed on the Nasdaq Capital Market under the symbol “EKSO”.
Liquidity and Capital Resources
As of March 31, 2022, the Company had an accumulated deficit of $213,487. Largely as a result of significant research and development activities related to the development of the Company’s advanced technology and commercialization of such technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. In the three months ended March 31, 2022, the Company used $4,206 of cash in its operations. Cash on hand as of March 31, 2022 was $36,176.
As described in Note 8, Notes payable, net, borrowings under the Company’s secured term loan agreement with Pacific Western Bank have a liquidity covenant requiring minimum cash on hand equivalent to the current outstanding principal balance. As of March 31, 2022, $2,000 of cash must remain as restricted. After considering cash restrictions, effective unrestricted cash as of March 31, 2022 is approximately $34,176. With this unrestricted cash balance, the Company believes that it currently has sufficient cash to fund its operations beyond the look forward period of one year from the issuance of these condensed consolidated financial statements.
2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates
Basis of Presentation and Consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 24, 2022.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2021, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein.
The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or any future periods.
The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.
Foreign Currency
The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss.
Inventory
Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw materials. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand. Subsequent disposals of inventories are recorded as a reduction of inventory.
Leases
The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received.
Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current.
Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.
Revenue Recognition
The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations. Revenue recognition is evaluated based on the following five steps: (i) identification of the contract with the customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.
For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not directly observable, judgment is made to estimate the selling price based on market conditions and entity-specific factors including cost plus analyses, features and functionality of the product and/or services, the geography of the Company’s customers, and type of the Company’s markets. Any discounts or other reductions to the transaction price are allocated proportionately to all performance obligations within the multiple-element arrangement. The Company periodically validates the stand-alone selling price for performance obligations by evaluating whether changes in the key assumptions used to determine the stand-alone selling prices will have a significant effect on the allocation of transaction price between multiple performance obligations.
The Company exercised judgement to determine that a product returns reserve was not required as historical returns activity have not been material.
Going Concern
The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern.
Concentration of Credit Risk and Other Risks and Uncertainties
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.
Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable as of March 31, 2022 and December 31, 2021. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.
At March 31, 2022, the Company had one customer (10%) with an accounts receivable balance totaling 10% or more of the Company’s total accounts receivable, as compared with zero customers at December 31, 2021.
During the three months ended March 31, 2022, the Company had one customer with sales of 10% or more of the Company’s total revenue (11%), as compared with two customers in the three months ended March 31, 2021 (14% and 11%, respectively).
Recent Accounting Pronouncements
In June 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2022-02, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update will be effective for the Company beginning in the first quarter of 2023. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its condensed consolidated financial statements and related disclosures.
In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity’s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective for the Company beginning in the first quarter of 2024 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. The Company does not expect the impact of adopting ASU 2020-06 to be material on its consolidated financial statements.
3. Accumulated Other Comprehensive Income (Loss)
The Company's accumulated other comprehensive income (loss) consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive income (loss) presented on the condensed consolidated balance sheets for the three months ended March 31, 2022 and 2021, is reflected in the table below net of tax:
| | | | | | | | |
| Three Months Ended March 31, |
| 2022 | 2021 |
Balance at beginning of period | $ | (17) | | $ | (847) | |
Net unrealized gain on foreign currency translation | 212 | | 465 | |
Balance at end of period | $ | 195 | | $ | (382) | |
4. Fair Value Measurement
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following:
•Level 1—Quoted prices in active markets for identical assets or liabilities. The Company considers a market to be active when transactions for the asset occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
•Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The valuation of Level 3 investments requires the use of significant management judgments or estimation.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
The Company’s fair value hierarchies for its financial assets and liabilities, which require fair value measurement on a recurring basis are as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Total | | Level 1 | | Level 2 | | Level 3 |
March 31, 2022 | | | | | | | | |
Liabilities | | | | | | | | |
Warrant liabilities | | $ | 1,650 | | | $ | — | | | $ | — | | | $ | 1,650 | |
| | | | | | | | |
December 31, 2021 | | | | | | | | |
Liabilities | | | | | | | | |
Warrant liabilities | | $ | 1,550 | | | $ | — | | | $ | — | | | $ | 1,550 | |
The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the period ended March 31, 2022, which were measured at fair value on a recurring basis:
| | | | | | | | |
| | Warrant Liability |
Balance at December 31, 2021 | | $ | 1,550 | |
| | |
Loss on revaluation of warrants issued in connection with the February 2021, June 2020, December 2019 and May 2019 financings | | 100 | |
| | |
Balance at March 31, 2022 | | $ | 1,650 | |
Refer to Note 10. Capitalization and Equity Structure – Warrants for additional information regarding the valuation of warrants.
5. Inventories
Inventories consisted of the following: | | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Raw materials | $ | 2,218 | | | $ | 2,061 | |
Work in progress | 308 | | | 145 | |
Finished goods | 246 | | | 36 | |
| | | |
| | | |
Inventories | $ | 2,772 | | | $ | 2,242 | |
6. Revenue
The Company’s medical device segment (EksoHealth) revenue is primarily generated through the sale and subscription of the EksoNR, associated software (SmartAssist and VariableAssist), the sale and subscription of the EksoUE, the sale of accessories, and the sale of support and maintenance contracts (Ekso Care). In 2021, the Company moved to a customer subscription sales model and away from a rental sales model. Under the rental sales model, the Company offered customers a short-term rental arrangement of its products to help bridge to a capital purchase since customers typically have challenges in obtaining approvals for capital expenditures. Subscription sales arrangements, however, bypass the customer capital purchase process, are intended to renew annually, and provide a long-term revenue stream.
Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility for sales of the EksoNR, software and accessories. Ekso Care support and maintenance contracts extend coverage beyond the Company’s standard warranty agreements. The separately priced Ekso Care contracts range from 12 to 48 months. The Company receives payment at the inception of the contract and recognizes revenue evenly over the term of the contracts. Revenue from medical device subscriptions is recognized evenly over the initial contract term, typically over 12 months.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
The Company’s industrial device segment (EksoWorks) revenue is generated through the sale of the upper body exoskeletons (EksoVest and the EVO) and the support arm (EksoZeroG). Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility.
Contract Balances
Timing of revenue recognition may differ from the timing of invoicing to customers and receipt of payment. For the sale of its products, the Company generally recognizes revenue at a point in time through the ship-and-bill performance obligations. For the subscription of its products, the Company generally recognizes revenue over the subscription term commencing upon the completion of customer training. For service agreements, the Company generally invoices customers at the beginning of the coverage period and records revenue related to the billed amounts over time, equivalent to the coverage period of the maintenance and support contract.
Deferred revenue is comprised mainly of unearned revenue related to extended support and maintenance contracts (Ekso Care), but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service.
Deferred revenue consisted of the following: | | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Deferred extended maintenance and support | $ | 2,124 | | | $ | 2,349 | |
Deferred royalties | — | | | 280 | |
Deferred device and advances | 73 | | | 66 | |
Total deferred revenues | 2,197 | | | 2,695 | |
Less current portion | (1,115) | | | (1,220) | |
Deferred revenues, non-current | $ | 1,082 | | | $ | 1,475 | |
Deferred revenue activity consisted of the following for the three months ended March 31, 2022: | | | | | |
| |
Beginning balance | $ | 2,695 | |
Deferral of revenue | 196 | |
Recognition of deferred revenue | (694) | |
Ending balance | $ | 2,197 | |
As of March 31, 2022, the Company’s deferred revenue was $2,197. The Company expects to recognize approximately $902 of the deferred revenue during the remainder of 2022, $681 in 2023, and $614 thereafter.
In addition to deferred revenue, the Company has a non-cancellable backlog of $1,524 related to its contracts for subscription units with its customers. These subscription contracts typically have 12-month terms and subscription income is recognized on a straight-line basis over the lease term.
In the three months ended March 31, 2022 the Company recognized revenue of $280 related to a $300 upfront royalty payment associated with a license and distribution agreement that expired. The unrecognized royalty balance of $280 was included in deferred revenue as of December 31, 2021.
As of March 31, 2022 and December 31, 2021, total accounts receivable, net of allowance for doubtful accounts, were $3,486 and $4,824, respectively, and are included in accounts receivable, net and other assets on the Company’s condensed consolidated balance sheets.
The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts, historical experience, and other currently
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 90 days.
Disaggregation of revenue
The following table disaggregates the Company’s revenue by major source for the three months ended March 31, 2022:
| | | | | | | | | | | | | | | | | |
| EksoHealth | | EksoWorks | | Total |
Device revenue | $ | 963 | | | $ | 309 | | | $ | 1,272 | |
Service and support | 467 | | | — | | | 467 | |
Subscriptions | 216 | | | 69 | | | 285 | |
Parts and other | 156 | | | 308 | | | 464 | |
Collaborative arrangements | 79 | | | — | | | 79 | |
| $ | 1,881 | | | $ | 686 | | | $ | 2,567 | |
The following table disaggregates the Company’s revenue by major source for the three months ended March 31, 2021:
| | | | | | | | | | | | | | | | | |
| EksoHealth | | EksoWorks | | Total |
Device revenue | $ | 1,019 | | | $ | 98 | | | $ | 1,117 | |
Service and support | 488 | | | — | | | 488 | |
Rentals and subscriptions | 152 | | | 70 | | | 222 | |
Parts and other | 54 | | | 15 | | | 69 | |
Collaborative arrangements | 14 | | | — | | | 14 | |
| $ | 1,727 | | | $ | 183 | | | $ | 1,910 | |
7. Accrued Liabilities
Accrued liabilities consisted of the following: | | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Salaries, benefits and related expenses | $ | 1,520 | | | $ | 2,015 | |
Device warranty | 226 | | | 195 | |
| | | |
| | | |
Other | 73 | | | 89 | |
Total | $ | 1,819 | | | $ | 2,299 | |
The current portion of the device warranty liability is classified as a component of accrued liabilities, while the long-term portion of the device warranty liability is classified as a component of other non-current liabilities in the condensed consolidated balance sheets. A reconciliation of the changes in the device warranty liability for the three months ended March 31, 2022 is as follows:
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 31, 2022 | | |
Balance at beginning of period | $ | 270 | | | | | | | |
Additions for estimated future costs | 76 | | | | | | | |
Incurred costs | (60) | | | | | | | |
Balance at end of period | $ | 286 | | | | | | | |
| | | | | | | |
| Balance as of March 31, 2022 |
Current portion | $ | 226 | |
Long-term portion | 60 | |
Total | $ | 286 | |
8. Notes Payable, net
PWB Term Loan
In August 2020, the Company entered into a new loan agreement (the "PWB Loan Agreement") with a lender, Pacific Western Bank, and received a loan in the principal amount of $2,000 (the "PWB Term Loan") that bears interest on the outstanding daily balance at a rate equal to the greater of: (a) 0.50% above the variable rate of interest announced by the lender as its “prime rate” then in effect; or (b) 4.50%. The PWB Loan Agreement created a first priority security interest with respect to substantially all assets of the Company, including proceeds of intellectual property, but expressly excluding intellectual property itself.
The Company is required to pay accrued interest on the current loan on the 13th day of each month through and including August 13, 2023. The principal balance of the PWB Term Loan matures on August 13, 2023, at which time all unpaid principal and accrued and unpaid interest shall be due and payable in full. The interest rate of the PWB Term Loan is subject to increase in the event of late payments and after occurrence of and during the continuation of an event of default. Upon maturity, all unpaid principal and accrued and unpaid interest shall be due and payable in full. The Company may elect to prepay the PWB Term Loan at any time, in whole or in part, without penalty or premium.
The PWB Loan Agreement contains a liquidity covenant, which requires that the Company maintain unrestricted cash and cash equivalents in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least the outstanding balance of the PWB Term Loan, which was $2,000 as of March 31, 2022. On March 31, 2022, with cash on hand of $36,176, the Company was compliant with this liquidity covenant and all other covenants.
The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest rate of 4.70% for the three months ended March 31, 2022. The debt issuance costs will be amortized to interest expense using the effective interest method over the life of the loan.
The following table presents scheduled principal payments of the Company’s PWB term loan as of March 31, 2022:
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | | | | | | |
Period | | Amount |
Remainder of 2022 | | $ | — | |
2023 | | 2,000 | |
Total principal payments | | 2,000 | |
Less debt discount and issuance cost | | 6 | |
Note payable, net | | $ | 1,994 | |
| | |
Current portion | | $ | — | |
Long-term portion | | 1,994 | |
Note payable, net | | $ | 1,994 | |
Paycheck Protection Program Loan
On April 20, 2020, the Company received an unsecured loan in the principal amount of $1,086 under the Paycheck Protection Program (the “PPP”) administered by the U.S. Small Business Administration (the "SBA"), pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), or the PPP loan. The PPP loan bore interest at 1.00% per annum, and matured two years after the date of initial disbursement. The terms of the PPP loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020, or the PPP Flexibility Act, which was enacted on June 5, 2020. The PPP loan was used for payroll costs, costs related to certain group health care benefits and insurance premiums, rent payments, utility payments and interest payments on other debt obligation that were incurred before February 15, 2020. Under the terms of the CARES Act and the PPP Flexibility Act, the Company could apply for and be granted forgiveness for all or a portion of loan granted under the PPP loan, with such forgiveness to be determined, subject to limitations (including where employees of the Company have been terminated and not re-hired by a certain date), based on the use of the loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The terms of any forgiveness were also subject to further requirements in regulations and guidelines adopted by the SBA.
On June 28, 2021, the Company received notification from the SBA that the Company’s Forgiveness Application of the PPP loan and accrued interest, totaling $1,099, was approved in full, and the Company had no further obligations related to the PPP loan. Accordingly, the Company recorded a gain on the forgiveness of the PPP loan as gain on forgiveness of note payable on the condensed consolidated statement of operations during the three months ended June 30, 2021.
9. Lease Obligations
The Company maintains a five-year operating lease agreement for its headquarters and manufacturing facility in Richmond, California (the "Richmond Lease") which expires in May 2022, with no further options to extend or terminate. The lease includes non-lease components (i.e. common area maintenance costs) that are paid separately from rent based on actual costs incurred.
The Company maintains a five-year operating lease agreement for its European operations office in Hamburg, Germany, which expires in July 2022. In February 2022, the Company executed a new lease agreement for a replacement office in Hamburg, Germany commencing May 1, 2022 and expiring June 30, 2025 with an option to renew for one five-year period. Since this operating lease commences after March 31, 2022, the lease payments are not recognized in lease liabilities and corresponding right-of-use assets on the balance sheet as of March 31, 2022.
The Company’s future lease payments as of March 31, 2022, which are presented as lease liabilities on the Company’s condensed consolidated balance sheets are as follows:
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | | | | | | |
Period | | Operating Leases |
Remainder of 2022 | | $ | 98 | |
2023 | | — | |
Total lease payments | | 98 | |
Less: imputed interest | | (1) | |
Present value of lease liabilities | | $ | 97 | |
| | |
Weighted-average remaining lease term (in years) | | 0.2 |
Weighted-average discount rate | | 10.5 | % |
Lease expense under the Company’s operating leases was $142 and $132 for the three months ended March 31, 2022 and 2021, respectively.
10. Capitalization and Equity Structure
Summary
The Company’s authorized capital stock at March 31, 2022 and December 31, 2021 consisted of 141,429 shares of common stock and 10,000 shares of preferred stock. As of March 31, 2022 and December 31, 2021, there were 12,844 and 12,693, respectively, shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.
Common Stock
February 2021 Offering
In February 2021, the Company entered into an amended and restated underwriting agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"), to sell 3,902 shares of the Company's common stock for a public price of $10.25 per share, for gross proceeds of $40,000 (the "February 2021 Offering"). The Company received net proceeds of $36,504 from the February 2021 Offering after deducting underwriting discounts, commissions and estimated offering expenses. Pursuant to the Underwriting Agreement, the Company issued, to certain designees of Wainwright, five year warrants (the “2021 Warrants”) to purchase shares of Common Stock in an amount equal to 7.0% of the aggregate number of shares sold in the February 2021 Offering, or 273 shares, at an exercise price of $12.81 per share.
At the Market Offering
In October 2020, the Company entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC (the "Agent"), under which the Company may issue and sell shares of its common stock, from time to time, to or through the Agent. The Company may offer and sell shares having an aggregate offering price of up to $7,500 under the registration statement and prospectus supplement filed with the SEC related to such offering. Under the ATM Agreement, shares of the Company's common stock may not be sold for a price lower than $6.75 per share. The Company did not sell any shares under the ATM agreement during the three months ended March 31, 2022. As of March 31, 2022, the Company has $6,668 available for future offerings under the prospectus filed with respect to the ATM Agreement.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Warrants
Warrants outstanding as of March 31, 2022 and December 31, 2021 were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Source | | Exercise Price | | Term (Years) | | December 31, 2021 | | Issued | | Exercised | | March 31, 2022 |
2021 Warrants | | $ | 12.81 | | | 5 | | 273 | | | — | | | — | | | 273 | |
June 2020 Investor Warrants | | $ | 5.18 | | | 5.5 | | 127 | | | — | | | — | | | 127 | |
June 2020 Placement Agent Warrants | | $ | 5.64 | | | 5 | | 39 | | | — | | | — | | | 39 | |
December 2019 Warrants | | $ | 8.10 | | | 5 | | 556 | | | — | | | — | | | 556 | |
December 2019 Placement Agent Warrants | | $ | 8.44 | | | 5 | | 52 | | | — | | | — | | | 52 | |
May 2019 Warrants | | $ | 3.52 | | | 5 | | 193 | | | — | | | — | | | 193 | |
| | | | | | 1,240 | | | — | | | — | | | 1,240 | |
During the three months ended March 31, 2021, the Company received net proceeds of $1,417 from the exercise of 358 warrants and issued 300 shares of common stock, respectively, as a result of those exercises. No warrants were exercised during the three months ended March 31, 2022.
2021 Warrants
In February 2021, the Company issued the 2021 Warrants, exercisable for up to 273 shares of the Company’s common stock at an exercise price of $12.81 per share. The 2021 Warrants were exercisable immediately, and will expire five years from the date of issuance, or on February 11, 2026.
In addition, the 2021 Warrants contain a cashless exercise provision, whereby, if, at the time a holder exercises its 2021 Warrants, a registration statement registering the issuance or the resale of the shares of common stock underlying the 2021 Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect to instead receive, upon such exercise (either in whole or in part), the net number of shares of the Company’s common stock determined according to a formula set forth in the 2021 Warrants. The 2021 Warrants will be automatically exercised on a cashless basis on their expiration date. The 2021 Warrants could also require payment of liquidated damages by the Company in the form of cash payments in the event of a failure by the Company to timely deliver shares of common stock upon exercise of such warrants.
The 2021 Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the 2021 Warrants, the Company or any successor entity will, at the option of a holder of a 2021 Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s 2021 Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s 2021 Warrant within five trading days after the notice of exercise by the holder of the put option. Because of this put-option provision, the 2021 Warrants are classified as a liability and are marked to market at each reporting date.
The warrant liability related to the 2021 Warrants is measured at fair value upon issuance and at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the 2021 Warrants:
| | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Current share price | $ | 2.89 | | | $ | 2.65 | |
Conversion price | $ | 12.81 | | | $ | 12.81 | |
Risk-free interest rate | 2.44 | % | | 1.13 | % |
Expected term (years) | 3.86 | | 4.11 |
Volatility of stock | 95.67 | % | | 98.3 | % |
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
June 2020 Investor Warrants
In June 2020, the Company issued warrants (the "June 2020 Investor Warrants"), exercisable for up to 874 shares of the Company’s common stock at an exercise price of $5.18 per share. The June 2020 Investor Warrants were immediately exercisable, and will expire five and one-half years from the date of issuance, or on December 10, 2025.
In addition, the June 2020 Investor Warrants contain a cashless exercise provision, whereby, if, at the time a holder exercises its June 2020 Investor Warrants, a registration statement registering the issuance or the resale of the shares of common stock underlying the June 2020 Investor Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect to instead receive, upon such exercise (either in whole or in part), the net number of shares of the Company’s common stock determined according to a formula set forth in the June 2020 Investor Warrant. The June 2020 Investor Warrants will be automatically exercised on a cashless basis on their expiration date.
The June 2020 Investor Warrants could also require payment of liquidated damages by the Company in the form of cash payments in the event of a failure by the Company to timely deliver shares of common stock upon exercise of such warrants. During the three months ended March 31, 2022 and 2021, no shares and 270 shares of the June 2020 Investor Warrants were exercised, respectively.
The June 2020 Investor Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the June 2020 Investor Warrants, the holders of the June 2020 Investor Warrants will be entitled to receive upon exercise of the June 2020 Investor Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the June 2020 Investor Warrants immediately prior to such fundamental transaction. Alternatively, the Company or any successor entity will, at the option of a holder of a June 2020 Investor Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s June 2020 Investor Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s June 2020 Investor Warrant. Because of this put-option provision, the June 2020 Investor Warrants are classified as a liability and are marked to market at each reporting date.
The warrant liability related to the June 2020 Investor Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Investor Warrants:
| | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Current share price | $ | 2.89 | | | $ | 2.65 | |
Conversion price | $ | 5.18 | | | $ | 5.18 | |
Risk-free interest rate | 2.44 | % | | 1.11 | % |
Expected term (years) | 3.69 | | 3.94 |
Volatility of stock | 97.1 | % | | 103.9 | % |
June 2020 Placement Agent Warrants
In June 2020, the Company issued warrants (the "June 2020 Placement Agent Warrants"), exercisable for up to 122 shares of the Company’s common stock, to the placement agent for such offering. The June 2020 Placement Agent Warrants have substantially the same form as the June 2020 Investor Warrants, including the put option described above, except that they have an exercise price per share equal to $5.64, subject to adjustment in certain circumstances, and will expire on June 7, 2025. During the three months ended March 31, 2022 and 2021, no shares and 83 shares of the June 2020 Placement Agent Warrants were exercised, respectively.
Because of the put-option provision in the June 2020 Placement Agent Warrants, these warrants are classified as a liability and are marked to market at each reporting date.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
The warrant liability related to the June 2020 Placement Agent Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Placement Agent Warrants:
| | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Current share price | $ | 2.89 | | | $ | 2.65 | |
Conversion price | $ | 5.64 | | | $ | 5.64 | |
Risk-free interest rate | 2.45 | % | | 1.03 | % |
Expected term (years) | 3.19 | | 3.44 |
Volatility of stock | 99.8 | % | | 100.0 | % |
December 2019 Warrants
In December 2019, pursuant to a securities purchase agreement (the "December 2019 Offering"), the Company issued warrants (the "December 2019 Warrants") to purchase 556 shares of common stock. The December 2019 Warrants are currently exercisable, have an exercise price of $8.10 per share, and will expire five years from the date they initially became exercisable, or on June 21, 2025.
The December 2019 Warrants also contain a cashless exercise provision and could require cash payments in the event of a failure to timely deliver securities or in the event of insufficient authorized shares. The December 2019 Warrants will be automatically exercised on a cashless basis on their expiration date. The December 2019 Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the December 2019 Warrants, the Company or any successor entity will, at the option of a holder of a December 2019 Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s December 2019 Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s December 2019 Warrant within five trading days after the notice of exercise by the holder of the put option. Because of this put-option provision, the December 2019 Warrants are classified as a liability and are marked to market at each reporting date.
The warrant liability related to the December 2019 Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Warrants:
| | | | | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 | |
Current share price | $ | 2.89 | | | $ | 2.65 | | |
Conversion price | $ | 8.10 | | | $ | 8.10 | | |
Risk-free interest rate | 2.45 | % | | 1.04 | % | |
Expected term (years) | 3.22 | | 3.47 | |
Volatility of stock | 99.5 | % | | 99.7 | % | |
December 2019 Placement Agent Warrants
In December 2019, in connection with the December 2019 Offering, the Company issued warrants to purchase 52 shares of the Company’s common stock to the placement agent for such offering (the "December 2019 Placement Agent Warrants"). The December 2019 Placement Agent Warrants have substantially the same form as the December 2019 Warrants, except that they have an exercise price per share equal to $8.44, subject to adjustment in certain circumstances, and will expire on December 18, 2025.
The warrant liability related to the December 2019 Placement Agent Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Placement Agent Warrants:
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Current share price | $ | 2.89 | | | $ | 2.65 | |
Conversion price | $ | 8.44 | | | $ | 8.44 | |
Risk-free interest rate | 2.4 | % | | 0.96 | % |
Expected term (years) | 2.72 | | 2.97 |
Volatility of stock | 103.5 | % | | 102.9 | % |
Management has assessed that the likelihood of a Change of Control (as defined in the December 2019 Placement Agent Warrants), occurring during the term of the December 2019 Placement Agent Warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the warrants fair value is nominal.
May 2019 Warrants
In May 2019, pursuant to an underwriting agreement, (the "May 2019 Offering"), the Company issued the warrants (the "May 2019 Warrants") to purchase 444 shares of common stock. The May 2019 Warrants are currently exercisable, have a current exercise price of $3.52 per share, and will expire five years from the date of their issuance, or on May 24, 2024. The May 2019 Warrants contain a price protection feature, pursuant to which, subject to certain exceptions, if shares of common stock are sold or issued in the future, or securities convertible or exercisable for shares of the Company’s common stock are sold or issued in the future, for consideration, or with an exercise price or conversion price, as applicable, per share less than the exercise price per share then in effect for the May 2019 Warrants, the exercise price of the May 2019 Warrants is reduced to the consideration paid for, or the exercise price or conversion price of, as the case may be, the securities issued in such offering. Pursuant to this provision, in connection with the June 2020 Offering, the exercise price of the May 2019 Warrants was reduced to $3.52 per share, being the amount that is equal to the lower of (x) the consideration paid for the securities issued in the June 2020 Offering, or $4.51 per share, (y) the lowest exercise price of the June 2020 Investor Warrants, or $5.18, and (z) the lowest one-day volume-weighted average price of the Company’s Common Stock on the Nasdaq Capital Market as measured each day during the five trading day period starting on June 8, 2020, rounded to the nearest share, or $3.52. During the three months ended March 31, 2022 and 2021, no shares and 5 shares of the May 2019 warrants were exercised respectively.
In addition, if the Company effects or enters into any issuance of common stock or options or convertible securities exercisable for or convertible into common stock at a price which varies or may vary with the market price of the shares of the Company's common stock, subject to certain exceptions, a May 2019 Warrant holder may, at the time of exercise of the holder’s warrant, elect to exercise the warrant at such variable price.
The May 2019 Warrants include a put option, whereby while the May 2019 Warrants are outstanding, if the Company enters into a Change of Control, as defined in the May 2019 Warrants, the Company or any successor entity will, at the option of a 2019 Warrant holder exercise within 90 days after the public disclosure of the Change of Control transaction, purchase such holder’s May 2019 Warrants by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such warrants on the later date of consummation of the Change of Control transaction or two trading days after the notice of such request. Because of this put option provision, the May 2019 Warrants are classified as a liability and are marked to market at each reporting date.
The warrant liability related to the May 2019 Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in a combination of the Black-Scholes Model and the Lattice Model to measure the fair value of the May 2019 Warrants:
| | | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 | |
Current share price | $ | 2.89 | | | $ | 2.65 | | |
Conversion price | $ | 3.52 | | | $ | 3.52 | | |
Risk-free interest rate | 2.31 | % | | 0.83 | % | |
Expected term (years) | 2.2 | | 2.4 | |
Volatility of stock | 108.6 | % | | 109.1 | % | |
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Management has assessed that the likelihood of a Change of Control occurring during the term of the warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the May 2019 Warrants fair value is nominal.
11. Stock-based Compensation
Shares available to grant
As of March 31, 2022, the total shares authorized for grant under the 2014 Plan was 1,974, of which 576 were available for future grants.
Stock Options
The following table summarizes information about the Company’s stock options outstanding as of March 31, 2022, and activity during the three months then ended:
| | | | | | | | | | | | | | | | | | | | | | | |
| Stock Awards | | Weighted- Average Exercise Price | | Weighted- Average Remaining Contractual Life (Years) | | Aggregate Intrinsic Value |
Balance as of December 31, 2021 | 491 | | | $ | 32.53 | | | | | |
| | | | | | | |
| | | | | | | |
Options forfeited | (26) | | | 10.58 | | | | | |
Options cancelled | (16) | | | 85.78 | | | | | |
Balance as of March 31, 2022 | 449 | | | $ | 31.96 | | | 5.12 | | $ | — | |
Vested and expected to vest at March 31, 2022 | 449 | | | $ | 31.96 | | | 5.12 | | $ | — | |
Exercisable as of March 31, 2022 | 402 | | | $ | 33.95 | | | 4.85 | | $ | — | |
As of March 31, 2022, total unrecognized compensation cost related to unvested stock options was $526. This amount is expected to be recognized as stock-based compensation expense in the Company’s condensed consolidated statements of operations and comprehensive loss over the remaining weighted average vesting period of 1.08 years.
Restricted Stock Units
The Company issues time-based restricted stock units (“RSUs”) and performance-based restricted stock units ("PSUs") to employees and non-employee service providers. Each RSU and PSU represents the right to receive one share of the Company’s common stock upon vesting and subsequent settlement. PSUs vest upon achievement of performance targets based on the Company's annual operating plan.
The fair values of RSUs and PSUs are determined based on the closing price of the Company’s common stock on the date of grant.
Combined RSU and PSU activity for the three months ended March 31, 2022 is summarized below:
| | | | | | | | | | | |
| Number of Shares | | Weighted- Average Grant Date Fair Value |
Unvested as of December 31, 2021 | 655 | | | $ | 5.63 | |
Granted | 195 | | | 2.59 | |
Vested | (127) | | | 5.59 | |
Forfeited | (142) | | | 5.39 | |
Unvested at March 31, 2022 | 581 | | | $ | 4.69 | |
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
As of March 31, 2022, $1,990 of total unrecognized compensation expense related to unvested RSUs and PSUs was expected to be recognized over a weighted average period of 1.72 years.
Compensation Expense
Total stock-based compensation expense related to options, RSUs and PSUs granted to employees is included in the condensed consolidated statements of operations and comprehensive loss as follows:
| | | | | | | | | | | | | | | |
| | | Three Months Ended March 31, |
| | | | | 2022 | | 2021 |
Sales and marketing | | | | | $ | 69 | | | $ | 99 | |
Research and development | | | | | 79 | | | 52 | |
General and administrative | | | | | 351 | | | 205 | |
| | | | | $ | 499 | | | $ | 356 | |